Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Basic Research in Cardiology
Metadata
Title
Evaluating the ‘no reflow’ phenomenon with myocardial contrast echocardiography
Author
S. Kaul, MD
Publication date
01-09-2006
Publisher
Steinkopff-Verlag
Published in
Basic Research in Cardiology / Issue 5/2006
Print ISSN: 0300-8428
Electronic ISSN: 1435-1803
DOI
https://doi.org/10.1007/s00395-006-0618-z

Other articles of this Issue 5/2006

Basic Research in Cardiology 5/2006 Go to the issue

FOCUSED ISSUE-No-reflow

Foreword – No-reflow: Basic science to a clinical phenomenon

ORIGINAL CONTRIBUTION

Activation of ERK and suppression of calcineurin are interacting mechanisms of cardioprotection afforded by δ-opioid receptor activation

INVITED EDITORIAL

The limits of endurance exercise

FOCUSED ISSUE-No-reflow

The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion

ORIGINAL CONTRIBUTION

β1-Adrenergic receptor antagonism abrogates cardioprotective effects of intermittent hypoxia

ORIGINAL CONTRIBUTION

Myocardial injury modulates the innate immune system and changes myocardial sensitivity

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits